FogPharma

We’re thrilled to announce a collaboration with the world-class team at ARTBIO that expands our pipeline of cancer therapies into #radiopharmaceuticals, a class of drugs we believe will make an extraordinary impact on patient outcomes. Along with ARTBIO we will be co-creating and co-commercializing Helicon-enabled alpha-particle radioligand therapies, drawing on the unique strengths of each of our platforms to produce a new category of targeted radioligand therapy. We believe the combination could produce the best radiopharmaceutical platform that exists in our industry today: On the one side, ARTBIO is uniquely able to accomplish distributed manufacturing of lead-212 (²¹²Pb), one of the most promising isotopes for radiopharmaceutical use but that is challenging to utilize because of its short half-life. On the other side, Fog’s Helicon platform could be a best-in-class carrier of radiopharmaceuticals because of our ability to precisely tune our peptides to control tissue distribution and half-life. The general hyper-tunability of Helicons opens new possibilities both for intracellular targeting — where Fog’s wholly-owned pipeline is focused — as well as for extracellular delivery. At the intersection of these two unmatched platforms, there’s huge potential to create therapies that improve, extend and save the lives of people with cancer. Learn more in our press release: https://bwnews.pr/3wBXF7L #radioligandtherapy #cancer #oncology #peptides #Helicons #radiopharmaceutical #patients

This week at #TIDESUSA, Yaguang Si, Ph.D., FogPharma’s Senior Director, Biology, will present on our preclinical development of Helicons™ as a potential treatment for cancer.    FOG-001, which is now in a first-in-human Phase 1/2 study, represents a long sought-after therapeutic approach in #cancer because of its ability to directly inhibit the β-catenin:TCF interaction that drives many cancers. YaGuang will present on our preclinical development of Helicon β-catenin inhibitors as novel alternatives for a range of cancers resulting from aberrant transcriptional signaling via β-catenin. https://bit.ly/3UAMXaM     #drugdiscovery #oncology #biotechnology

We’re #hiring for 4 exciting roles in our technical operations team, supporting the development, manufacturing, and supply of Fog’s investigational medicines in current and future research and clinical studies. We’re looking for company-builders who can leverage Fog’s unique position and opportunity to deliver life-changing medicines for patients with devastating diseases. We’re specifically hiring the following positions:   - Vice President, Manufacturing, a highly influential role reporting to Chief Technical Operations Officer Rohin Mhatre, Ph.D., who will make a significant impact managing our manufacturing network and directing our manufacturing strategy to enable cost-effective supply of clinical and future commercial products worldwide.    - Director, Clinical Supply Operations, who will ensure high-quality and consistent supply of our investigational medicines as we prosecute clinical trials for first-in-class cancer therapies.   - Principal Associate Scientist (Formulation), who will conduct studies to develop and implement fit-for-purpose formulations for our investigational Helicon therapeutics. - Process Chemist, who will establish robust manufacturing processes for Fog’s therapeutic candidates by leveraging modern synthetic methodology.    Learn more about these roles: https://bit.ly/3VSwmAx         #biotechjobs #drugdiscovery #technicaloperations

FogPharma CEO Mathai Mammen, M.D., Ph.D., will be at the rEVOLUTION Symposium this week in Washington, DC, to moderate a panel on the inevitability and utility of AI in the development of therapies for patients. The rEVOLUTION meeting is held every 1-2 years in DC, and brings together thought leaders to tackle some of R&D’s most significant challenges. The location also allows significant participation by DC’s policymakers and regulators.   Joining Mathai for this important discussion will be Nicolle Gatto, Ph.D., Chief Scientific Officer at Aetion; Najat Khan, PhD, Former Chief Data Science Officer & Global Head, Strategy & Portfolio, R&D at Johnson & Johnson; Eric Schadt, Ph.D., Chief Scientific Officer at Pathos; and other leaders.    AI, and data science broadly, are technologies we’re passionate about at FogPharma. Today, a lot of attention is being paid to the role of data science in drug discovery, but in fact some of the biggest gains in the near term will be made in drug development. Numerous resource-intensive, strategically critical drug development challenges — including clinical site selection, patient recruitment, protocol design, endpoint definition, responder and non-responder signatures, and synthetic control arms — will be revolutionized by data science in the coming years.   At Fog, we hope to combine experimental science and these sorts of data science advances to revolutionize the discovery and development of transformational medicines.    Explore the rEVOLUTION event agenda here:  https://bit.ly/44jUIoH   #drugdiscovery #artificialIntelligence #datascience #oncology

From eclipse to espresso! April was full of fun moments for #TeamFogPharma. The team took time to bond over our new foosball table with a little friendly competition, got outside for the totality solar eclipse event, celebrated employee anniversaries and enjoyed the first installment of a monthly breakfast where we can enjoy the diverse cultures and foods of our staff.    These events highlight the close-knit community we have here at Fog with initiatives that not only enhance inclusion and a sense of belonging, but foster relationships that support us as we seek to deliver nothing short of extraordinary impact for patients.   Check out some of the highlights!

Say hello to the newest member of #TeamFogPharma, Judy Zdanowicz, who joins the Fog leadership team as Vice President of Quality! Judy has a deep well of expertise in leading cross-functional quality teams across the drug development lifecycle, from R&D to commercialization. We’re excited for the essential role Judy will play in ensuring that our programs are shaped for clinical and commercial readiness from their earliest stages. Welcome, Judy!

We’re looking for extraordinary individuals to join #TeamFogPharma. Check out the roles we’re hiring for below and here: https://bit.ly/4d1lKVM

We’re looking forward to leading, facilitating and participating in several industry meetings over the next few weeks. Check them out below 👇 and hope to see you there. #oncology #drugdiscovery

Recently, our CEO Mathai Mammen, M.D., Ph.D., moderated a panel at the R&D Leadership Summit hosted by The Conference Forum about the biopharma industry’s important role in ensuring lifesaving therapies are accessible to patients around the world. At FogPharma, we’re committed to building a company that is able to serve patients around the globe, no matter which country they live in. We know to accomplish this, we must be as innovative in our operations and strategic planning as we are in our labs. Thanks to the event’s organizers for convening discussion on such an important topic for our industry. #FogPharma #drugdiscovery #oncology #datascience

We’re proud to announce the promotion of Fog Scientific Co-Founder John McGee, Ph.D., to Senior Vice President of Platform Technology this month. Click through below to see John’s thoughts on the evolution of Fog since the early days.    #TeamFogPharma #oncology #datascience #drugdiscovery